Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1-1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi Life Science Investing
Seer to Showcase AI-Driven Multi-Cancer Screening Approach and Next-Generation Proteomics Capabilities at ASMS 2026 Life Science Investing
Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts Life Science Investing
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference Life Science Investing
BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data Life Science Investing
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society Congress Life Science Investing
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides Life Science Investing
RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP Platform Presented at the 2026 ASCO Annual Meeting Life Science Investing
PRF Technologies Announces PRF-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical Study Life Science Investing
